Clinical trials: Second-Line
Metastatic Colorectal Cancer
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or…
- Trial name
- NCT06060704
- Testing
- Envafolimab, Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Immunotherapy, Second-line Treatment
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
- Trial name
- NCT05901584
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
- Trial name
- NCT01951157
- Testing
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Acute Myeloid Leukaemia (AML)
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is…
- Trial name
- NCT06788756
- Testing
- Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 312 people
- Sponsor
- Moleculin Biotech, Inc.
Follicular Lymphoma
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory…
- Trial name
- NCT06911502
- Testing
- Golcadomide, Rituximab, Lenalidomide
- Where
- 160 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- Celgene
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer.
- Conditions
- Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
- Trial name
- COBRA (NCT04038502)
- Testing
- Carboplatin, Olaparib
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Small Cell Lung Cancer (SCLC)
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
This study is a multicenter, open-label, single-arm phase 2 study of irinotecan liposome injection in patients with small cell lung cancer (SCLC) who have progressed after platinum-based first-line therapy.
- Trial name
- NCT04727853
- Testing
- irinotecan liposome injection
- Where
- China
- Volunteers
- 66 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Optimization of Second Line Treatment Protocol for H Pylori Eradication
Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection
The aim of this study is to evaluate the efficacy of sequential therapy, i.e. 5 days of PPI + amoxicillin followed by 5 days of PPI + two antimicrobial drugs( clarithromycin and tinidazole ) versus quadruple drug regimen( i.e.-14…
- Trial name
- NCT01481844
- Testing
- Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole, Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline
- Where
- Israel
- Volunteers
- 101 people
- Sponsor
- Soroka University Medical Center
Gastric / Gastroesophageal Junction Adenocarcinoma
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin
This study is an open, exploratory clinical study. Eligible patients with advanced second-line gastric/gastroesophageal junction adenocarcinoma signed an informed consent form, were screened for enrollment, and were entered into…
- Trial name
- NCT06030934
- Testing
- envafolimab and lenvatinib combined with paclitaxel-albumin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Colorectal Cancer
A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT01181609
- Testing
- bevacizumab [Avastin]
- Where
- 16 sites in France
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Cholangiocarcinoma, Gallbladder Cancer
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- BOLSTER (NCT05712356)
- Testing
- certepetide, Durvalumab, Cisplatin
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- Lisata Therapeutics, Inc.
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
This phase II trial compares the effects of lenvatinib given in combination with everolimus to the effects of cabozantinib given alone in treating patients with renal cell cancer (RCC) that has spread to other parts of the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05012371
- Testing
- Cabozantinib, Everolimus, Lenvatinib
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Safety and Efficacy
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4 aGVHD is systemic glucocorticoid.
- Trial name
- NCT05021276
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303745
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- 23 sites in France
- Volunteers
- 78 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Lymphoma, Non-Hodgkin
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma
- Trial name
- NCT02072967
- Testing
- Ribomustin, rituximab
- Where
- 35 sites in Russia
- Volunteers
- 97 people
- Sponsor
- Astellas Pharma Europe B.V.
Metastatic Renal Cell Carcinoma
Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib
This is a nation-wide retrospective observational study which will be performed in 50 centres in Spain, geographically representative of all regions, with at least 5 patients treated with first-line pazopanib for mRCC in daily…
- Trial name
- Spazo-2 (NCT03091465)
- Where
- 57 sites in Spain
- Volunteers
- 530 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and…
- Trial name
- NCT01133756
- Testing
- Lenvatinib, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.
Mantle Cell Lymphoma
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients with first relapsed/refractory mantle cell lymphoma…
- Trial name
- R2-B (NCT01737177)
- Testing
- Bendamustine, Lenalidomide, Rituximab
- Where
- 43 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Chronic Myeloid Leukemia (CML) in
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
This study is testing a new way to treat people with a type of blood cancer called chronic myeloid leukemia (CML) in chronic phase.
- Trial name
- NCT07538401
- Testing
- No high risk mutation, High Risk Mutation
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.